Bioreactors

“We want it so every child in the world can pick up a crayon and color the sky and have that crayon that they pick is blue, right, and today that’s not the reality for every kid around the world,” Zara Summers, Chief Science Officer at LanzaTech, a Biotech Company, vividly articulates the company’s goal to reduce fossil fuel consumption and instead, recycle carbon, that is already above ground to create necessities.

In the ever-evolving landscape of biopharmaceutical processes development, companies are constantly seeking ways to enhance efficiency and streamline their operations. One formidable combination that has been gaining momentum is the use of a powerful and easy to use batch planning strategy with eve bioprocessing software and parallel bioreactors Multifors. In this article, we will delve into how the combination of these two tools can enable you to potentiate process development.

As the workhorses of life, proteins fulfil a variety of functions in our bodies. If their functionality is limited or missing, diseases can arise. Therefore, proteins and their production are a central key to research. Whether protein expression is to be controlled for experimental, biotechnological, or medical applications, the use of cells is often mandatory. Many researchers repeatedly face the same challenge of producing complex target protein fast and cheap. Transient transfection of recombinant plasmids (rpDNA) in mammalian cells is a popular method for this purpose. In the following article, we look at the success story of research assistant Damian von Blarer, who must produce specific regions of the famous SARS-CoV-2 spike protein for efficiency studies of a rapid test – for this he needs plasmids, and we show which questions you need to answer to produce and amplify them easily yourself.

The idea of using our own cells to produce antibodies essential for survival no longer belongs to science fiction. Although it has been the focus of researchers for decades, the direct use of messenger RNA encoding antibodies has received recent market approval due to the urgency of the COVID-19 pandemic. As such, this platform technology is revolutionizing the way we think about biopharmaceutical production and has great potential for further applications. In the following article, you will learn about the key aspects of the application, production and use of mRNA, the software of life.

A cross-interdisciplinary collaboration is increasing the sustainable value creation in Norwegian aquaculture and agriculture by using industrial by-products as a nutrient source for yeast-based Single Cell Protein (SCP). The microbial ingredient is used as a high-value locally produced protein source in animal feed with health-promoting components. But how to meet the demand for more biomass? The success story of the Norwegian University of Life Sciences (NMBU) shows us a way to increase production capacity.